Aim: To identify the inhibition of TNF-induced NF-kappaB nuclear translocation by three anti-human TNF mAbs, D2, E6 and F6.
Methods: TNF solutions were pretreated with mAbs D2, E6 and F6 as well as control mAb at 37 degrees Celsius for 1 h, respectively, and then they were added to ECV304 cell cultures. After 1 hour, the cells were harvested and nuclear proteins were extracted. The NF-kappaB activity in nuclear extract was detected by electrophoretic mobility shift assay (EMSA).
Results: All of the three anti-TNF mAbs could inhibit TNF-induced NF-kappaB nuclear translocation in a dose-dependent manner. At the concentrations of 10 mg/L and 0.1 mg/L, the inhibition rates of mAb D2, E6 and F6 were 94.2% and 75.1%, 64.9% and 28.6%, 70.3% and 49.5% respectively, while the inhibition rate of control mAb was only 20.0% and 11.1%.
Conclusion: mAbs D2, E6 and F6 can specifically inhibit TNF-induced NF-kappaB nuclear translocation, which lays the foundation for preparation of therapeutic chimeric anti-human TNF antibody for treatment of infectious and autoimmune diseases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Novel Quinoline Inhibitor of the Canonical NF-κB Transcription Factor Pathway.
Biology (Basel)
November 2024
Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly, 41335 Larissa, Greece.
The NF-κB family of transcription factors is a master regulator of cellular responses during inflammation, and its dysregulation has been linked to chronic inflammatory diseases, such as inflammatory bowel disease. It is therefore of vital importance to design and test new effective NF-κB inhibitors that have the potential to be utilized in clinical practice. In this study, we used a commercial transgenic HeLa cell line as an NF-κB activation reporter to test a novel quinoline molecule, Q3, as a potential inhibitor of the canonical NF-κB pathway.
View Article and Find Full Text PDFComplex IIa formation and ABC transporters determine sensitivity of OSCC to Smac mimetics.
Cell Death Dis
November 2024
Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, China.
Small molecule inhibitors of apoptosis proteins (IAPs) antagonists, known as Smac mimetics (SMs), activate non-canonical NF-κB and sensitize cancer cells to TNF-induced cell death. SMs are currently in phase III clinical trials for head and neck squamous cell carcinoma (HNSCC) after promising phase II trials. To explore the utility of SMs in oral squamous cell carcinoma (OSCC), we tested nine human OSCC cell lines and correlated SM sensitivity with both IAP mutation and expression levels.
View Article and Find Full Text PDFNF-κB regulated expression of A20 controls IKK dependent repression of RIPK1 induced cell death in activated T cells.
Cell Death Differ
September 2024
Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, The Pears Building, Hampstead, London, UK.
Article Synopsis
- * In activated T cells, IKK2 deficiency leads to impaired proliferation and makes them more susceptible to TNF-induced cell death, which can be rescued by inhibiting RIPK1 activity.
- * Gene expression analysis shows that A20, a regulator of NF-κB, is under-expressed in IKK2 deficient T cells, and both A20 and IKK2 are essential for T cell survival; their combined deficiency results in a significant loss of T cells, which can be reversed by inhibiting RIPK1.
E3 ubiquitin ligase gene modulates TNF-induced cell death pathways and promotes aberrant proliferation in rheumatoid arthritis fibroblast-like synoviocytes.
Front Immunol
September 2024
Department of Rheumatology, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Article Synopsis
- Rheumatoid arthritis (RA) is an autoimmune disease that leads to inflammation of the joints, primarily driven by fibroblast-like synoviocytes (FLS) which produce inflammatory substances like TNF-α and IL-6.
- FLS in RA behave similarly to tumors, proliferating aggressively and resisting cell death, contributing to joint damage.
- Targeting E3 ubiquitin ligases like cIAP2 may offer potential treatments for RA by reducing inflammation and FLS survival, though the potential side effects of these treatments need further investigation.
Cyld restrains the hyperactivation of synovial fibroblasts in inflammatory arthritis by regulating the TAK1/IKK2 signaling axis.
Cell Death Dis
August 2024
Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center (BSRC) "Alexander Fleming", Vari, Greece.
TNF is a potent cytokine known for its involvement in physiology and pathology. In Rheumatoid Arthritis (RA), persistent TNF signals cause aberrant activation of synovial fibroblasts (SFs), the resident cells crucially involved in the inflammatory and destructive responses of the affected synovial membrane. However, the molecular switches that control the pathogenic activation of SFs remain poorly defined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!